Trial Profile

A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Firtecan pegol (Primary)
Indications Neuroblastoma; Solid tumours
Focus Adverse reactions
Sponsors Enzon Pharmaceuticals

Most Recent Events

29 Jan 2022 Status changed from active, no longer recruiting to discontinued.
19 Jun 2012 Primary endpoint 'Recommended-phase-II-dose' has been met.
19 Jun 2012 Results have been presented at the 2012 Advances in Neuroblastoma Research Conference according to an Enzon Pharmaceuticals media release. Results were also summarised in the media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com